Buserelin

GnRH Agonist (long-acting)

Also known as: Suprefact · Profact

A synthetic GnRH agonist used for prostate cancer, endometriosis, & infertility treatment. Available as nasal spray & depot injection.

Typical Dose

200–500 mcg 3x/day intranasal or 0.5 mg SubQ daily (induction); then depot

Route

Subcutaneous or intranasal

Cycle

Clinical protocol dependent

Half-life

~2–3 hours (SubQ); sustained nasal

Storage

Per manufacturer.

Overview

Buserelin is a synthetic nonapeptide GnRH agonist with D-serine(tBu) at position 6, approved for prostate cancer, endometriosis, & as part of controlled ovarian hyperstimulation in IVF protocols (to prevent premature LH surge).

Quick Start Guide

Clinical use only. Administered as daily SubQ, nasal spray, or depot depending on indication.

Research Indications

Prostate cancer

Most Effective

Equivalent to other GnRH agonists for testosterone suppression.

Controlled ovarian hyperstimulation (IVF)

Most Effective

Prevents premature LH surge in IVF protocols.

Research Protocols

Prostate cancer

Ongoing

Dose

3.6 mg depot implant

Frequency

Every 8 weeks

Route

SubQ

Side Effects & Safety

Common

Hot flashes
Decreased libido
Injection site reactions

Uncommon

Depression
Osteoporosis (long term)

When to Stop

Signs of allergic reaction
Flare risk with bone metastases

How to Reconstitute

Commercial product. Reconstitute per package insert.

Dosing math: Clinical use only.

Quality Indicators

Good — use as normal

Per manufacturer

Discard immediately

Any deviation from manufacturer specification

What to Expect

Week 1–4

Testosterone suppression follows initial flare.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample